Aplidin in patients with advanced dedifferentiated liposarcomas: A French Sarcoma Group Single-Arm Phase II study

Annals of Oncology

Volumn 26, Issue 7, 2015, Pages 1465-1470

  Toulmonde, M ^a   Le Cesne, A ^b   Piperno Neumann, S ^c   Penel, N ^d   Chevreau, C ^e   Duffaud, F ^f   Bellera, C ^a,g   Italiano, Antoine ^a  

^a INSTITUT BERGONIÉ   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c INSTITUT CURIE   (France)

^d CENTRE OSCAR LAMBRET   (France)

^e INSTITUT CLAUDIUS REGAUD   (France)

^f TIMONE HOSPITAL   (France)

^g CTD INCa   (France)

Author keywords

Aplidin; Dedifferentiated liposarcoma; Jun; Plitidepsin; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; DEHYDRODIDEMNIN B; TROPONIN T; DEPSIPEPTIDE;

ADULT; AGED; ANEMIA; ANOREXIA; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; DEDIFFERENTIATED LIPOSARCOMA; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HYPOALBUMINEMIA; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; VOMITING; WEIGHT REDUCTION; CANCER STAGING; CLINICAL TRIAL; DISEASE COURSE; FOLLOW UP; LIPOSARCOMA; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DEPSIPEPTIDES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOSARCOMA; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 84946494831     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv195     Document Type: Article

References (35)

1. Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. Pathology and genetics of tumours of soft tissue and bone. In Kleihues P (ed), World Health Organisation Classification of Tumours, Edition. Lyon, France: IARC Press, 2013.
2. Italiano A, Bianchini L, Keslair F et al. HMGA2 is the partner of MDM2 in welldifferentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer 2008; 122: 2233-2241.
3. Binh MB, Sastre-Garau X, Guillou L et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol 2005; 29: 1340-1347.
4. Aleixo PB, Hartmann AA, Menezes IC et al. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. J Clin Pathol 2009; 62:1127-1135.
5. Coindre JM, Mariani O, Chibon F et al. Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. Mod Pathol 2003; 16:256-262.
6. de Vreeze RS, de Jong D, Nederlof PM et al. Added value of molecular biological analysis in diagnosis and clinical management of liposarcoma: a 30-year singleinstitution experience. Ann Surg Oncol 2010; 17: 686-693.
7. Coindre JM, Pedeutour F, Aurias A. Well-differentiated and dedifferentiated liposarcomas. Virchows Arch 2010; 456: 167-179.
8. Henricks WH, Chu YC, Goldblum JR, Weiss SW. Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol 1997; 21: 271-281.
9. Dalal KM, Kattan MW, Antonescu CR et al. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg 2006; 244: 381-391.
10. Mussi C, Collini P, Miceli R et al. The prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of surgically treated patients at a single institution. Cancer 2008; 113: 1657-1665.
11. Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg 2003; 238: 358-370; discussion 370-351.
12. Italiano A, Toulmonde M, Cioffi A et al. Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Ann Oncol 2012; 23: 1601-1607.
13. Sanfilippo R, Bertulli R, Marrari A et al. High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. Clin Sarcoma Res 2014; 4: 16.
14. Chibon F, Mariani O, Derré J et al. MAP3K5 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14-q15 and 6q23 amplifications. Genes Chromosomes Cancer 2004; 40: 32-37.
15. Mariani O, Brennetot C, Coindre JM et al. JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell 2007; 4: 361-374.
16. Faivre S, Chièze S, Delbaldo C et al. Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. J Clin Oncol 2005; 23: 7871-7880.
17. Cuadrado A, Gonzalez L, Suarez Y et al. JNK activation is critical for Aplidininduced apoptosis. Oncogene 2004; 23(27): 4673-4680.
18. Mitsiades CS, Ocio EM, Pandiella A et al. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res 2008; 68: 5216-5225.
19. Losada A, Lopez-Oliva JM, Sanchez-Puelles JM, Garcia-Fernandez LF. Establishment and characterisation of a human carcinoma cell line with acquired resistance to Aplidin. Br J Cancer 2004; 91: 1405-1413.
20. Bravo SB, Garcia-Rendueles ME, Seoane R et al. Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma. Clin Cancer Res 2005; 11: 7664-7673.
21. Munoz-Alonso MJ, Gonzalez-Santiago L, Zarich N et al. Plitidepsin has a dual effect inhibiting cell cycle and inducing apoptosis via rac1/c-jun nh2-terminal kinase activation in human melanoma cells. J Pharmacol Exp Ther 2008; 324:1093-1101.
22. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
23. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
24. Van Glabbeke M, Verweij J, Judson I, Nielsen OS; EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002; 38: 543-549.
25. Chen P-L, Riley DJ, Chen Y, Lee W-H. Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs. Genes Dev 1996; 10: 2794-2804.
26. Snyder EL, Sandstrom DJ, Law K et al. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. J Pathol 2009; 218: 292-300.
27. Chibon F, Mariani O, Derre J et al. A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas. Cancer Genet Cytogenet 2002; 139: 24-29.
28. Schöffski P, Guillem V, Garcia M et al. Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma. Mar Drugs 2009; 7: 57-70.
29. Ribrag V, Caballero D, Fermé C et al. Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma. Haematologica 2013; 98: 357-363.
30. Soto-Matos A, Szyldergemajn S, Extremera S et al. Plitidepsin has a safe cardiac profile: a comprehensive analysis. Mar Drugs 2011; 9: 1007-1023.
31. Müller CR, Paulsen EB, Noordhuis P et al. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer 2007; 121: 199-205.
32. Ray-Coquard I, Blay JY, Italiano A et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 2012; 13: 1133-1140.
33. Siu L, Italiano A, Miller W et al. Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients ( pts) with solid tumors. J Clin Oncol 2014; 32(5 suppl); abstr 2535.
34. Dickson MA, Tap WD, Keohan ML et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol 2013; 31: 2024-2028.
35. Italiano A, Bianchini L, Gjernes E et al. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res 2009; 15: 5696-5703.